Shares of I-Mab (IMAB) touched a new 52-week high of $6.72 yesterday as the company gears up to present updated Givastomig monotherapy data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025.
Givastomig, the company's lead drug candidate, is a bispecific antibody targeting Claudin 18.2-positive tumor cells. It conditionally activates T cells through the 4-1BB signalling pathway in the tumour microenvironment, where CLDN18.2 is expressed. CLDN18.2 is a protein that is often expressed in various cancer types, including gastric and gastroesophageal adenocarcinomas. (Source: PubMed).
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com